140 related articles for article (PubMed ID: 36815510)
21. [Endocervical adenocarcinomas classified by International Endocervical Adenocarcinoma Criteria and Classification: a clinicopathological and prognostic analysis of 286 cases].
Lyu BJ; Shi HY; Shao Y; Liu Q; Lyu WG
Zhonghua Bing Li Xue Za Zhi; 2021 Sep; 50(9):1014-1019. PubMed ID: 34496491
[No Abstract] [Full Text] [Related]
22. Molecular and immunological characteristics of patients with CMTM6 low expression colorectal cancer.
Lu ZM; Pan SL; Yuan WL; Feng JL; Tian D; Shang XQ
Medicine (Baltimore); 2023 Dec; 102(50):e36480. PubMed ID: 38115316
[TBL] [Abstract][Full Text] [Related]
23. CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
Zhang S; Yan Q; Wei S; Feng X; Xue M; Liu L; Cui J; Zhang Y
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Aug; 132(2):202-209. PubMed ID: 34034998
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic and prognostic significance of CMTM6 and PD-L1 expression in cervical squamous cell carcinoma.
Ma H; Shi S; Ma Z; Sun J; Liu X; Niu S; Liu H; Zhang Z
Int J Clin Exp Pathol; 2023; 16(12):368-377. PubMed ID: 38188349
[TBL] [Abstract][Full Text] [Related]
25. Construction of stable membranal CMTM6-PD-L1 full-length complex to evaluate the PD-1/PD-L1-CMTM6 interaction and develop anti-tumor anti-CMTM6 nanobody.
Jia XM; Long YR; Yu XL; Chen RQ; Gong LK; Geng Y
Acta Pharmacol Sin; 2023 May; 44(5):1095-1104. PubMed ID: 36418428
[TBL] [Abstract][Full Text] [Related]
26. The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Ishihara S; Iwasaki T; Kohashi K; Yamada Y; Toda Y; Ito Y; Susuki Y; Kawaguchi K; Takamatsu D; Kawatoko S; Kiyozawa D; Mori T; Kinoshita I; Yamamoto H; Fujiwara T; Setsu N; Endo M; Matsumoto Y; Nakashima Y; Oda Y
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2003-2011. PubMed ID: 33811537
[TBL] [Abstract][Full Text] [Related]
27. High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence.
Muranushi R; Araki K; Yokobori T; Chingunjav B; Hoshino K; Dolgormaa G; Hagiwara K; Yamanaka T; Ishii N; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Harimoto N; Shimoda Y; Sano R; Oyama T; Saeki H; Shirabe K
Cancer Sci; 2021 Aug; 112(8):3314-3323. PubMed ID: 34080242
[TBL] [Abstract][Full Text] [Related]
28. The predictive value and correlation of β-catenin, CMTM6, and PD-L1 expression in colorectal cancer.
Li B; Wu S; Qiu Z; Zhong X; Chen Z; Luo F; Li J; Liu K
Neoplasma; 2022 May; 69(3):691-699. PubMed ID: 35293763
[TBL] [Abstract][Full Text] [Related]
29. Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer.
Zhang C; Zhao S; Wang X
Cancer Cell Int; 2021 Jan; 21(1):78. PubMed ID: 33509216
[TBL] [Abstract][Full Text] [Related]
30. Single-Cell Landscape Highlights Heterogenous Microenvironment, Novel Immune Reaction Patterns, Potential Biomarkers and Unique Therapeutic Strategies of Cervical Squamous Carcinoma, Human Papillomavirus-Associated (HPVA) and Non-HPVA Adenocarcinoma.
Qiu J; Qu X; Wang Y; Guo C; Lv B; Jiang Q; Su W; Wang L; Hua K
Adv Sci (Weinh); 2023 Apr; 10(10):e2204951. PubMed ID: 36725337
[TBL] [Abstract][Full Text] [Related]
31. Tumor-associated CD204
Kawachi A; Yoshida H; Kitano S; Ino Y; Kato T; Hiraoka N
Cancer Sci; 2018 Mar; 109(3):863-870. PubMed ID: 29274107
[TBL] [Abstract][Full Text] [Related]
32. Analysis of Immunological Characteristics and Genomic Alterations in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Based on PD-L1 Expression.
Xu SM; Shi CJ; Xia RH; Wang LZ; Tian Z; Ye WM; Liu L; Liu SL; Zhang CY; Hu YH; Zhou R; Han Y; Wang Y; Zhang ZY; Li J
Front Immunol; 2021; 12():798424. PubMed ID: 35145511
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Algorithmic Proposal Based on Comprehensive Immunohistochemical Evaluation of 297 Invasive Endocervical Adenocarcinomas.
Stolnicu S; Barsan I; Hoang L; Patel P; Chiriboga L; Terinte C; Pesci A; Aviel-Ronen S; Kiyokawa T; Alvarado-Cabrero I; Pike MC; Oliva E; Park KJ; Soslow RA
Am J Surg Pathol; 2018 Aug; 42(8):989-1000. PubMed ID: 29851704
[TBL] [Abstract][Full Text] [Related]
34. The clinical and prognostic significance of CMTM6/PD-L1 in oncology.
Yaseen MM; Abuharfeil NM; Darmani H
Clin Transl Oncol; 2022 Aug; 24(8):1478-1491. PubMed ID: 35278198
[TBL] [Abstract][Full Text] [Related]
35. Expression and Clinical Significance of
Shi S; Ma HY; Sang YZ; Ju YB; Liu XY; Zhang ZG
Biomed Res Int; 2022; 2022():8118909. PubMed ID: 35845949
[TBL] [Abstract][Full Text] [Related]
36. CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis.
Jia D; Xiong L; Xue H; Li J
PeerJ; 2023; 11():e14668. PubMed ID: 36643629
[TBL] [Abstract][Full Text] [Related]
37. CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.
Zhang T; Yu H; Dai X; Zhang X
Front Immunol; 2022; 13():971428. PubMed ID: 35958549
[TBL] [Abstract][Full Text] [Related]
38. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
39. HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer.
Liu Y; Li X; Zhang H; Zhang M; Wei Y
Oncogene; 2021 Mar; 40(12):2230-2242. PubMed ID: 33649535
[TBL] [Abstract][Full Text] [Related]
40. Quantitative analysis of CMTM6 expression in tumor microenvironment in metastatic melanoma and association with outcome on immunotherapy.
Martinez-Morilla S; Zugazagoitia J; Wong PF; Kluger HM; Rimm DL
Oncoimmunology; 2020 Dec; 10(1):1864909. PubMed ID: 33457084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
